DOCSLIB.ORG

Pharmacology of Ophthalmic Agents

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pharmacology of Ophthalmic Agents Ophthalmic Pharmacology Richard Alan Lewis M.D., M.S., PHARMACOLOGY FOPS PHARMACOKINETICS OF Professor, Departments of Ophthalmology, • The study of the absorption, OPHTHALMIC Medicine, Pediatrics, and Molecular distribution, metabolism, AGENTS and Human Genetics and excretion of a drug or and the National School of Tropical agent Introduction and Review Medicine Houston, Texas PHARMACOKINETICS Factors Affecting Drug Penetration Factors Affecting Drug Penetration into Ocular Tissues • A drug can be delivered to ocular tissue: into Ocular Tissues – Locally: • Drug concentration and solubility: The higher the concentration the better the penetration, • Surfactants: The preservatives in ocular • Eye drop but limited by reflex tearing. preparations alter cell membrane in the cornea • Ointment and increase drug permeability, e.g., • Viscosity: Addition of methylcellulose and benzalkonium and thiomersal • Periocular injection polyvinyl alcohol increases drug penetration by • pH: The normal tear pH is 7.4; if the drug pH is • Intraocular injection increasing the contact time with the cornea and altering corneal epithelium. much different, it will cause reflex tearing. – Systemically: • Lipid solubility: Because of the lipid rich • Drug tonicity: When an alkaloid drug is put in • Orally environment of the epithelial cell membranes, relatively alkaloid medium, the proportion of the uncharged form will increase, thus more • IM the higher lipid solubility, the more the penetration. • IV penetration. FLUORESCEIN FLUORESCEIN Chemistry Dosage ● C20H1205, brown crystal ● Adults: 500-750 mg IV ● M.W. 322.3 e.g., 3 cc 25% solution ● Peak absorption 485-500 nm. 5 cc 10% solution ● Peak emission 520-530 nm. ● Children: 1.5-2.5 mg/kg IV Richard Alan Lewis, M.D., M.S. Nov 2013 1 Ophthalmic Pharmacology Needle Diameter Ideal Flow through a small FLUORESCEIN tube varies with the 4th power Needle Outer Diameter Inner Diameter Side Effects of the radius (r4) Gauge mm mm Gauge r r4 ● Skin staining: 100% (6-12 hours) 18 1.270 0.838 20 0.3015 ~0.00826 ● Aqueous staining: 100% (8-24 hours) 20 0.908 0.603 ● Urine staining: 100% (24-36 hours) 21 0.819 0.514 21 0.257 ~0.00436 23 0.641 0.337 0.00826/0.00436 = 1.895 25 0.514 0.260 FLUORESCEIN ANGIOGRAPHY FLUORESCEIN ANGIOGRAPHY FLUORESCEIN Adverse Reactions Adverse Reactions Adverse Reactions Do not change with: ● Local Effects Reported with: - Extravascular - Informed consent - Intravenous ● Topical phenylephrine - NPO state - Intra-arterial ● Venipuncture - Premedication ● Systemic Effects ● Fundus photography - Mild - Dye concentration - Moderate - Severe FLUORESCEIN FLUORESCEIN FLUORESCEIN Extravasation Extravasation Intravenous ● Intense local pain ● Think prevention ● Dull ache, ipsilateral extremity ● Warm, wet compress, - Duration: 20 - 45 minutes Chemical thrombophlebitis 30 minutes Q.I.D. - Management: self-limited Duration: 3-10 days ● Examine site at 24°, 48° reassurance Management: self-limited cold pack ● If avascular, refer to plastic ● Dermal necrosis surgeon Richard Alan Lewis, M.D., M.S. Nov 2013 2 Ophthalmic Pharmacology FLUORESCEIN FLUORESCEIN ANGIOGRAPHY FLUORESCEIN ANGIOGRAPHY Intra-arterial Mild Adverse Reactions Mild Adverse Reactions ● Immediate INTENSE stain of ● Nausea and vomiting < 5% ● Transient distal extremity ● Extravasation ● Rapid and complete ● PAIN! ● Sneezing resolution - Duration: 1-24 hours ● Pruritus ● No treatment required - Management: Cold, Analgesia FLUORESCEIN ANGIOGRAPHY FLUORESCEIN ANGIOGRAPHY FLUORESCEIN ANGIOGRAPHY Moderate Adverse Reactions Moderate Adverse Reactions Severe Adverse Reactions ● Urticaria (1.2%) ● Transient • Prolonged ● Syncope (0.3%) ● Medical therapy required • Intense therapy required ● ● Complete, if gradual, Thrombophlebitis resolution with no sequelae ● Local tissue necrosis • Threat to patient safety ● Nerve palsy • Variable recovery Overall: 1.6% FLUORESCEIN ANGIOGRAPHY FLUORESCEIN FLUORESCEIN ANGIOGRAPHY Severe Adverse Reactions Toxicity Death ● Respiratory (1:3,800) - Laryngeal stridor, edema - Bronchospasm ● Phototoxicity to skin - Anaphylaxis ● Cardiovascular (1:5,300) (Premature, jaundiced infant, Death rate: 1:220,000 - Circulatory shock - Myocardial infarction, arrest UV therapy: J Peds: 1985; 107) ● Neurological (1:13,900) - Seizure (Overall: 1:1,900) Richard Alan Lewis, M.D., M.S. Nov 2013 3 Ophthalmic Pharmacology FLUORESCEIN FLUORESCEIN FLUORESCEIN Precautions Precautions Prophylaxis: Nausea • Not approved for use in pregnancy • No evidence for teratogenicity, • Does NOT cross-react with embryocidicity iodinated contrast dyes Metoclopramide HCl • Not approved for use in children • Avoid patients with prior • Renal insufficiency prolongs serious reactions to fluorescein (Reglan) 20 mg IV elimination • Avoid historically risky patients • Diabetics should not confuse color 5 min before F/A with reactions for glucose ADVERSE REACTIONS FLUORESCEIN ANGIOGRAPHY MANAGEMENT Management Screening ● Trained personnel ● Consent form, especially children ● Emergency equipment ● History of prior allergies, asthma - Airway (oral, AMBU) Not routinely conducted - A negative history is no - O2 (mask, prongs cylinder) guarantee of impunity - Parenteral fluids on pregnant subjects ● History of recent change in angina, (I.V. stand, fluids, sets) uncontrolled hypertension, - B/P cuff cardiac arrhythmia - Drugs DRUGS for ANAPHYLACTOID FLUORESCEIN ANGIOGRAPHY Most serious reactions REACTIONS occur within minutes of Diphenhydramine (Benadryl) 25-50 mg p.o., i.m., i.v. injection. Severe Informed Consent Tripelennamine (Pyribenzamine) anaphylactoid reactions 25-50 mg p.o. may develop as late as Fexofenadine (Allegra) one hour after injection. 180 mg. p.o. Richard Alan Lewis, M.D., M.S. Nov 2013 4 Ophthalmic Pharmacology INDOCYANINE GREEN INDOCYANINE GREEN Therefore, if there is Description Formulation any suspicion, the Tricarbocyanine dye with •Contains 5% Nal patient should wait peak spectral •pH 5.5 - 6.5 and be absorption at 800-810 nm, •Unstable in observed. emission at 830-840 nm, in blood. aqueous solution INDOCYANINE GREEN INDOCYANINE GREEN INDOCYANINE GREEN Chemistry Indications Dosage ● Ophthalmic angiography • 0.5 mg/kg (<2 mg/kg) •C H N NaO S 43 47 2 6 2 ● Cardiac output • Adults: 40 mg in 2 ml •M.W. 774.96 ● Hepatic function, blood flow solvent with 5 cc N.S. flush INDOCYANINE GREEN INDOCYANINE GREEN INDOCYANINE GREEN Pharmacology Contraindications Adverse Reactions • Anaphylaxis, urticaria ● Bound to plasma proteins ● Diluent contains Nal reported, without (albumin, 95%) ● Avoid allergy to iodides ● Hepatic secretion to bile allergy to iodides • 2 deaths reported Richard Alan Lewis, M.D., M.S. Nov 2013 5 Ophthalmic Pharmacology Iodine/Iodide Allergy INDOCYANINE GREEN VERTEPORFIN Pregnancy • NO objective evidence • Trade Name: Visudyne demonstrates cross- • Safety in pregnancy, • Formula: C H N O nursing not established 41 42 4 8 reactivity between • Isomers of benzoporphorin allergy to shellfish and • No animal embryocidicity, teratogenicity studies • Molecular Weight: 718.8 iodine sensitivity! J. Emerg. Med. 2010: 39 (5): 701-707 VERTEPORFIN VERTEPORFIN VERTEPORFIN Indication Metabolism Adverse Reactions ● Skeletal: back pain, 2-15% Light-activated drug for • Liver excretion into ● Skin: photosensitivity (5 days) photodynamic therapy of bile, feces ● GI: nausea various subretinal • Half-life 5-6 hours ● CV: syncope, hypotension, neovascularizations bradycardia VERTEPORFIN VERTEPORFIN VERTEPORFIN Contraindications Other Cautions Precautions • Photosensitization, • Pregnancy class C • Porphyria ~ 5 days • Liver dysfunction • Rats: anophthalmia • Avoid extravasation • Known hypersensitivity • Avoid nursing • Matched laser 689 nm. Richard Alan Lewis, M.D., M.S. Nov 2013 6 Ophthalmic Pharmacology VERTEPORFIN PEGAPTANIB Cautions PEGAPTANIB Macugen • Trade name: Macugen ● Avoid other photosensitizers • Mechanism of Action: (thiazides, sulfas, antidiabetics • Formula: ● 83 sec. treatment, exactly 15 C294H342F13N107Na28O188P28 Selective antagonist of min. after 10 min. infusion [C2H4O]n, where n = ~900 Vascular Endothelial • Molecular Wt: ~50 kD Growth Factor (VEGF) PEGAPTANIB PEGAPTANIB PEGAPTANIB Macugen Macugen Macugen • Mechanism: An aptamer, • Dose: 0.3 mg intravitreous • Indication: ‘Wet’ macular modified RNA oligonucleotide, degeneration that adopts the 3-dimensional • Frequency: Every 6 weeks conformation to bind to • Half-life: ~ 10 days • Contraindications: ocular infections; extracellular VEGF165 inhibiting • Metabolism: Degraded by its binding to VEGF receptors. nucleases known sensitivity PEGAPTANIB PEGAPTANIB RANIBIZUMAB Macugen-Safety Macugen • Trade name: Lucentis • Pregnancy: Not studied • Supplied: in a prefilled, • Formula: recombinant • Nursing: Not studied single use, glass syringe, humanized IgG1 κ • Children: Not studied with 0.3 mg Macugen, monoclonal antibody • Safety or efficacy not packaged with 30 G x ½” fragment proven beyond 2 years BD needle • Molecular wt.: 48 kD Richard Alan Lewis, M.D., M.S. Nov 2013 7 Ophthalmic Pharmacology RANIBIZUMAB RANIBIZUMAB Lucentis Lucentis • Indication: “Wet” • Dose: 0.5 mg intravitreous macular degeneration • Frequency: q month x 4, • Contraindications: then q 3 months sensitivity; active • Half-life: 7 – 12 days ocular infections RANIBIZUMAB RANIBIZUMAB RANIBIZUMAB Lucentis Lucentis Lucentis • Mechanism of action: • Cautions: • Side Effects: Binds to all receptor Transient elevation of subconjunctival binding sites of VEGF-A, intraocular pressure; hemorrhage, pain, preventing
Load more

Recommended publications
  • Drug-Induced Angle-Closure Glaucoma
    10.5005/jp-journals-10008-1100 ArujREVIEW K Khurana ARTICLE et al Drug-induced Angle-Closure Glaucoma Aruj K Khurana, Bhawna Khurana, Ashok K Khurana Regional Institute of Ophthalmology, Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India Correspondence: Ashok K Khurana, Senior Professor, Regional Institute of Ophthalmology, Post Graduate Institute of Medical Sciences, Rohtak, Haryana, India ABSTRACT Drug-induced angle-closure glaucoma is an important entity for the ophthalmologist as well as the general physician as it represents a preventable cause of potential blindness. This brief review highlights the fact that a high index of suspicion, in a susceptible individual followed by confirmation on appropriate imaging modality (UBM, ultrasound or anterior segment OCT) can alleviate the threat to sight and also help to institute appropriate therapy. Keywords: Acute angle closure, Drug-induced glaucoma. INTRODUCTION factors exist for this syndrome.9 Other sulfa-based drugs known Drug-induced angle-closure glaucoma is an important entity to be associated with AACG: Acetazolamide, hydrochloro- 10 for the ophthalmologist as well as the general physician as it thiazide and cotrimoxazole. represents a preventable cause of potential blindness.1 Acute Anticholinergic drugs implicated in the causation of AACG angle-closure glaucoma can develop in a susceptible individual include atropine, homatropine, cyclopentolate and ipratropium by various classes of drugs.2 Practitioners using any of these bromide.10,11 Atropine is often used to treat bradycardia, drugs should be aware of their potential to cause acute angle especially related to general anesthesia. Postoperative AACG closure, such that a patient presenting with signs or symptoms has been reported in patients after general anesthesia for of acute angle closure should be immediately referred to an abdominal, orthopedic, facial and endoscopic surgery.12 3 ophthalmologist.
    [Show full text]
  • Non-Steroidal Drug-Induced Glaucoma MR Razeghinejad Et Al 972
    Eye (2011) 25, 971–980 & 2011 Macmillan Publishers Limited All rights reserved 0950-222X/11 www.nature.com/eye 1,2 1 1 Non-steroidal drug- MR Razeghinejad , MJ Pro and LJ Katz REVIEW induced glaucoma Abstract vision. The majority of drugs listed as contraindicated in glaucoma are concerned with Numerous systemically used drugs are CAG. These medications may incite an attack in involved in drug-induced glaucoma. Most those individuals with narrow iridocorneal reported cases of non-steroidal drug-induced angle.3 At least one-third of acute closed-angle glaucoma are closed-angle glaucoma (CAG). glaucoma (ACAG) cases are related to an Indeed, many routinely used drugs that have over-the-counter or prescription drug.1 Prevalence sympathomimetic or parasympatholytic of narrow angles in whites from the Framingham properties can cause pupillary block CAG in study was 3.8%. Narrow angles are more individuals with narrow iridocorneal angle. The resulting acute glaucoma occurs much common in the Asian population. A study of a more commonly unilaterally and only rarely Vietnamese population estimated a prevalence 4 bilaterally. CAG secondary to sulfa drugs is a of occludable angles at 8.5%. The reported bilateral non-pupillary block type and is due prevalence of elevated IOP months to years to forward movement of iris–lens diaphragm, after controlling ACAG with laser iridotomy 5,6 which occurs in individuals with narrow or ranges from 24 to 72%. Additionally, a open iridocorneal angle. A few agents, significant decrease in retinal nerve fiber layer including antineoplastics, may induce thickness and an increase in the cup/disc ratio open-angle glaucoma.
    [Show full text]
  • Totalcare Medicaid 2017 Q2 GB
    Preferred Drug List Molina Healthcare of New York, Inc. 2017 *Molina mandates the use of generic drugs, if available. Brand names listed are for reference only. THIS LIST IS SUBJECT TO CHANGE. You can get more information and updates to this document on our website at www.molinahealthcare.com MCD_CO_ESIPREFDRUGQ3_0817_08/27/2017 6025633NY0417 Table of Contents Anti - Infectives....................................................................................................................................................3 Antineoplastic / Immunosuppressant Drugs ......................................................................................................12 Autonomic / Cns Drugs, Neurology / Psych ......................................................................................................17 Cardiovascular, Hypertension / Lipids...............................................................................................................34 Dermatologicals/Topical Therapy......................................................................................................................41 Diagnostics / Miscellaneous Agents ..................................................................................................................56 Ear, Nose / Throat Medications..........................................................................................................................64 Endocrine/Diabetes ............................................................................................................................................66
    [Show full text]
  • Abcd (Ipratropium Bromide and Albuterol Sulfate) Inhalation Aerosol
    ATTENTION PHARMACIST: Detach “Patient’s Instructions for Use” from package insert and dispense with the product. Combivent® abcd (ipratropium bromide and albuterol sulfate) Inhalation Aerosol Bronchodilator Aerosol For Oral Inhalation Only Rx only Prescribing Information DESCRIPTION COMBIVENT Inhalation Aerosol is a combination of ipratropium bromide (as the monohydrate) and albuterol sulfate. Ipratropium bromide is an anticholinergic bronchodilator chemically described as 8-azoniabicyclo[3.2.1] octane, 3-(3-hydroxy-1-oxo-2-phenylpropoxy)-8-methyl­ 8-(1-methylethyl)-, bromide monohydrate, (3-endo, 8-syn)-: a synthetic quaternary ammonium compound chemically related to atropine. Ipratropium bromide is a white to off-white crystalline substance, freely soluble in water and methanol, sparingly soluble in ethanol, and insoluble in lipophilic solvents such as ether, chloroform, and fluorocarbons. The structural formula is: + N OH Br­ . H O H 2 O O C20H30BrNO3•H2O ipratropium bromide Mol. Wt. 430.4 Albuterol sulfate, chemically known as (1,3-benzenedimethanol, α'-[[(1,1dimethylethyl) amino] methyl]-4-hydroxy, sulfate (2:1)(salt), (±)- is a relatively selective beta2-adrenergic bronchodilator. Albuterol is the official generic name in the United States. The World Health Organization recommended name for the drug is salbutamol. Albuterol sulfate is a white to off-white crystalline powder, freely soluble in water and slightly soluble in alcohol, chloroform, and ether. The structural formula is: Reference ID: 2927161 OH NH * . H2SO4 OH OH 2 (C13H21NO3)2•H2SO4 albuterol sulfate Mol. Wt. 576.7 Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol contains a microcrystalline suspension of ipratropium bromide and albuterol sulfate in a pressurized metered-dose aerosol unit for oral inhalation administration.
    [Show full text]
  • Anticholinergic Drugs and Dementia
    DEMENTIA Q&A 24 Anticholinergic drugs and dementia Anticholinergics are a class of drug used to treat a wide variety of medical conditions. As with any medication, anticholinergics can have many beneficial effects, but these need to be balanced against a number of potential risks. This sheet provides information about how these drugs work as well as the impact that they may have in respect to dementia risk and cognitive functioning. What are anticholinergics? in time.4 It has been estimated that in Australia, 33% of people over the age of 65 years take enough Anticholinergics are generally used to inhibit the medications with anticholinergic effects to potentially involuntary movements of muscles or balance the increase their risk of harm.5 The use of anticholinergics production of various chemicals within the body. They is more common in older people because these drugs have been used in treating a wide variety of medical are prescribed for the symptomatic management of conditions including symptoms of psychosis (which medical conditions that often occur in later life. can be caused by bipolar disorder and schizophrenia), depression, urinary incontinence (e.g. overactive How do anticholinergic drugs work? bladder), gastrointestinal spasms, allergies, respiratory Anticholinergics are a class of drug that block the conditions (such as asthma and chronic obstructive action of acetylcholine in the nervous system, a pulmonary disease), Parkinson’s disease, conditions chemical (neurotransmitter) that is used to control concerning muscles in the eye and pupil dilation, messages travelling from one cell to another. They do nausea, sleep disorders and cardiovascular complaints this by blocking the binding of acetylcholine to its (slow heart rhythms) (Table 1).1,2 Some cold and flu receptor in the nerve cells.
    [Show full text]
  • Pharmaceuticals Appendix
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ADAPALENE 106685-40-9 ABANOQUIL 90402-40-7 ADAPROLOL 101479-70-3 ABECARNIL 111841-85-1 ADEMETIONINE 17176-17-9 ABLUKAST 96566-25-5 ADENOSINE PHOSPHATE 61-19-8 ABUNIDAZOLE 91017-58-2 ADIBENDAN 100510-33-6 ACADESINE 2627-69-2 ADICILLIN 525-94-0 ACAMPROSATE 77337-76-9 ADIMOLOL 78459-19-5 ACAPRAZINE 55485-20-6 ADINAZOLAM 37115-32-5 ACARBOSE 56180-94-0 ADIPHENINE 64-95-9 ACEBROCHOL 514-50-1 ADIPIODONE 606-17-7 ACEBURIC ACID 26976-72-7 ADITEREN 56066-19-4 ACEBUTOLOL 37517-30-9 ADITOPRIME 56066-63-8 ACECAINIDE 32795-44-1 ADOSOPINE 88124-26-9 ACECARBROMAL 77-66-7 ADOZELESIN 110314-48-2 ACECLIDINE 827-61-2 ADRAFINIL 63547-13-7 ACECLOFENAC 89796-99-6 ADRENALONE 99-45-6 ACEDAPSONE 77-46-3 AFALANINE 2901-75-9 ACEDIASULFONE SODIUM 127-60-6 AFLOQUALONE 56287-74-2 ACEDOBEN 556-08-1 AFUROLOL 65776-67-2 ACEFLURANOL 80595-73-9 AGANODINE 86696-87-9 ACEFURTIAMINE 10072-48-7 AKLOMIDE 3011-89-0 ACEFYLLINE CLOFIBROL 70788-27-1
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub
    US 2002O187986A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0187986 A1 Horn (43) Pub. Date: Dec. 12, 2002 (54) OPHTHALMIC FORMULATION WHICH Related U.S. Application Data MODULATES DILATION (62) Division of application No. 09/710,758, filed on Nov. (76) Inventor: Gerald Horn, Deerfield, IL (US) 8, 2000, now Pat. No. 6,420,407. Publication Classification Correspondence Address: Bell, Boyd & Lloyd LLC (51) Int. Cl." .................. A61K 31/517; A61K 31/4745; P.O. BOX 1135 A61K 31/4168; A61K 31/4164 Chicago, IL 60690 (US) (52) U.S. Cl. ..................... 514/252.17; 514/283; 514/401 (57) ABSTRACT (21) Appl. No.: 10/165,459 An ophthalmic formulation is disclosed which reduces dila (22) Filed: Jun. 7, 2002 tion in dim light and reduces redness. US 2002/0187986 A1 Dec. 12, 2002 OPHTHALMC FORMULATION WHICH 0007 A formulation for optimizing pupil size in extreme MODULATES DILATION lighting conditions is disclosed. The formulation is prefer ably a Solution of the type used in an artificial tear formu FIELD OF THE INVENTION lation having dissolved therein a therapeutically effective 0001. The present invention relates to a composition amount of a compound characterized by its ability to reduce formulated and administered to a human eye to reduce dilation of the eye, particularly in dim light. The compound dilation and redness. generally interferes with a natural biochemical reaction which results in the stimulation of the dilator muscles of the BACKGROUND OF THE INVENTION eye. The formulation is preferably further comprised of a compound which reduces eye redness, e.g.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Patent Application Publication ( 10 ) Pub . No . : US 2019 / 0192440 A1
    US 20190192440A1 (19 ) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0192440 A1 LI (43 ) Pub . Date : Jun . 27 , 2019 ( 54 ) ORAL DRUG DOSAGE FORM COMPRISING Publication Classification DRUG IN THE FORM OF NANOPARTICLES (51 ) Int . CI. A61K 9 / 20 (2006 .01 ) ( 71 ) Applicant: Triastek , Inc. , Nanjing ( CN ) A61K 9 /00 ( 2006 . 01) A61K 31/ 192 ( 2006 .01 ) (72 ) Inventor : Xiaoling LI , Dublin , CA (US ) A61K 9 / 24 ( 2006 .01 ) ( 52 ) U . S . CI. ( 21 ) Appl. No. : 16 /289 ,499 CPC . .. .. A61K 9 /2031 (2013 . 01 ) ; A61K 9 /0065 ( 22 ) Filed : Feb . 28 , 2019 (2013 .01 ) ; A61K 9 / 209 ( 2013 .01 ) ; A61K 9 /2027 ( 2013 .01 ) ; A61K 31/ 192 ( 2013. 01 ) ; Related U . S . Application Data A61K 9 /2072 ( 2013 .01 ) (63 ) Continuation of application No. 16 /028 ,305 , filed on Jul. 5 , 2018 , now Pat . No . 10 , 258 ,575 , which is a (57 ) ABSTRACT continuation of application No . 15 / 173 ,596 , filed on The present disclosure provides a stable solid pharmaceuti Jun . 3 , 2016 . cal dosage form for oral administration . The dosage form (60 ) Provisional application No . 62 /313 ,092 , filed on Mar. includes a substrate that forms at least one compartment and 24 , 2016 , provisional application No . 62 / 296 , 087 , a drug content loaded into the compartment. The dosage filed on Feb . 17 , 2016 , provisional application No . form is so designed that the active pharmaceutical ingredient 62 / 170, 645 , filed on Jun . 3 , 2015 . of the drug content is released in a controlled manner. Patent Application Publication Jun . 27 , 2019 Sheet 1 of 20 US 2019 /0192440 A1 FIG .
    [Show full text]
  • Additional Drug Coverage
    Additional Drug Coverage Additional prescription drug coverage Your plan includes extra coverage for certain drugs and supplies as shown below. This is not a complete list of prescription drugs and supplies covered by our plan. For a complete list, please call Customer Service toll-free at (866) 868-0609 (TTY: 711), 7 a.m. – 7 p.m. CT, Monday – Friday and 7 a.m. – 3 p.m. CT, Saturday. Lower-cost Medicare prescription drugs and supplies Your plan covers some of your Medicare prescription drugs and supplies at a $0 copay. If you have questions, call us toll-free at (866) 868-0609 (TTY: 711), 7 a.m. – 7 p.m. CT, Monday – Friday and 7 a.m. – 3 p.m. CT, Saturday. These drugs and supplies are part of your Medicare prescription drug coverage.1 Breast cancer preventive medications PEG-3350/NaCl/Na Bicarbonate/KCl TriLyte Anastrozole Exemestane Certain diabetic supplies for the Raloxifene administration of insulin Tamoxifen Insulin Syringes & Pen Needles Certain cholesterol-lowering medications Shingles vaccine Atorvastatin 10mg & 20mg Tablet Shingrix Lovastatin 10mg, 20mg & 40mg Tablet Zostavax Simvastatin 5mg, 10mg, 20mg & 40mg Tablet Tobacco cessation medications Certain colon prep products Buproban 150mg GaviLyte-C Chantix GaviLyte-G Nicotrol Inhaler PEG-3350/Electrolytes Nicotrol Nasal Spray Y0066_200527_081500_C Lower-cost non-Medicare over-the-counter drugs These drugs are covered in addition to the drugs in your plan’s drug list (formulary).2 Your plan covers these over-the-counter drugs at a $0 copay. Certain colon preparation products Tobacco cessation medications Bisacodyl Tablets Nicotine Gum Magnesium Citrate Solution Nicotine Lozenges Polyethylene Glycol Powder Nicotine Patches 1Information about the appeals and grievance process for these prescription drugs and supplies can be found in your Evidence of Coverage.
    [Show full text]
  • Pharmacology for Respiratory Care 1
    RESP-1340: Pharmacology for Respiratory Care 1 RESP-1340: PHARMACOLOGY FOR RESPIRATORY CARE Cuyahoga Community College Viewing: RESP-1340 : Pharmacology for Respiratory Care Board of Trustees: March 2020 Academic Term: Fall 2020 Subject Code RESP - Respiratory Care Course Number: 1340 Title: Pharmacology for Respiratory Care Catalog Description: General principles of pharmacology and calculations of drug dosages. Discussion of pharmacologic principles and agents used in treatment of cardiopulmonary disorders. Credit Hour(s): 2 Lecture Hour(s): 2 Lab Hour(s): 0 Other Hour(s): 0 Requisites Prerequisite and Corequisite RESP-1300 Respiratory Care Equipment and RESP-1310 Cardiopulmonary Physiology. Outcomes Course Outcome(s): A. Evaluate specific information on various categories of drugs. Objective(s): 1. Demonstrate an understanding of basic terminology for respiratory care pharmacology. 2. Identify the official drug publication in the U.S. 3. Identify four common sources of drug information. Course Outcome(s): B. Describe the basic principles of drug action emphasizing the pharmaceutical phase, pharmacokinetic phase and pharmacodynamic phase. Objective(s): 1. Identify the three phases involved in drug action. 2. Identify five different routes of administration and give advantages and disadvantages of each route. 3. Identify the four processes involved in the pharmacokinetics phase. 4. Identify the essential concepts involved with the interaction of a drug molecule with its target receptor site. 2 RESP-1340: Pharmacology for Respiratory Care Course Outcome(s): C. Calculate and interpret adult dosages for medications given by respiratory care practitioners. Objective(s): 1. Calculate dosages from percentage strength solutions. 2. Calculate the amount of solute per ml of solution given a ratio.
    [Show full text]
  • Marrakesh Agreement Establishing the World Trade Organization
    No. 31874 Multilateral Marrakesh Agreement establishing the World Trade Organ ization (with final act, annexes and protocol). Concluded at Marrakesh on 15 April 1994 Authentic texts: English, French and Spanish. Registered by the Director-General of the World Trade Organization, acting on behalf of the Parties, on 1 June 1995. Multilat ral Accord de Marrakech instituant l©Organisation mondiale du commerce (avec acte final, annexes et protocole). Conclu Marrakech le 15 avril 1994 Textes authentiques : anglais, français et espagnol. Enregistré par le Directeur général de l'Organisation mondiale du com merce, agissant au nom des Parties, le 1er juin 1995. Vol. 1867, 1-31874 4_________United Nations — Treaty Series • Nations Unies — Recueil des Traités 1995 Table of contents Table des matières Indice [Volume 1867] FINAL ACT EMBODYING THE RESULTS OF THE URUGUAY ROUND OF MULTILATERAL TRADE NEGOTIATIONS ACTE FINAL REPRENANT LES RESULTATS DES NEGOCIATIONS COMMERCIALES MULTILATERALES DU CYCLE D©URUGUAY ACTA FINAL EN QUE SE INCORPOR N LOS RESULTADOS DE LA RONDA URUGUAY DE NEGOCIACIONES COMERCIALES MULTILATERALES SIGNATURES - SIGNATURES - FIRMAS MINISTERIAL DECISIONS, DECLARATIONS AND UNDERSTANDING DECISIONS, DECLARATIONS ET MEMORANDUM D©ACCORD MINISTERIELS DECISIONES, DECLARACIONES Y ENTEND MIENTO MINISTERIALES MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION ACCORD DE MARRAKECH INSTITUANT L©ORGANISATION MONDIALE DU COMMERCE ACUERDO DE MARRAKECH POR EL QUE SE ESTABLECE LA ORGANIZACI N MUND1AL DEL COMERCIO ANNEX 1 ANNEXE 1 ANEXO 1 ANNEX
    [Show full text]